Media headlines about Rhythm Pharmaceuticals (NASDAQ:RYTM) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.9427812963841 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Morgan Stanley Initiates Coverage on Rhythm Pharmaceuticals, Inc. (RYTM) (americanbankingnews.com)
- Rhythm Pharmaceuticals, Inc. (RYTM) Now Covered by Analysts at Needham & Company LLC (americanbankingnews.com)
- Rhythm Pharmaceuticals, Inc. (RYTM) Earns Buy Rating from Analysts at Bank of America Corporation (americanbankingnews.com)
- Orphan Disease IPO, Rhythm Pharmaceuticals: Initiating Coverage With Buy Rating And $34 Price Target (40% Upside) (seekingalpha.com)
- 13D Filing: OrbiMed Advisors and Rhythm Pharmaceuticals Inc (RYTM) (insidermonkey.com)
Rhythm Pharmaceuticals (NASDAQ RYTM) traded up 2.95% during midday trading on Monday, reaching $24.42. 149,310 shares of the company’s stock traded hands. Rhythm Pharmaceuticals has a one year low of $21.38 and a one year high of $33.81. The stock’s market cap is $636.73 million. The stock’s 50 day moving average price is $24.23 and its 200-day moving average price is $24.23.
Several equities research analysts have commented on RYTM shares. Morgan Stanley started coverage on shares of Rhythm Pharmaceuticals in a report on Monday. They set an “equal weight” rating and a $23.00 price objective on the stock. Needham & Company LLC started coverage on shares of Rhythm Pharmaceuticals in a report on Monday. They set a “buy” rating and a $32.00 price objective on the stock. Cowen and Company started coverage on shares of Rhythm Pharmaceuticals in a report on Monday. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Bank of America Corporation started coverage on shares of Rhythm Pharmaceuticals in a report on Monday. They set a “buy” rating and a $30.00 price objective on the stock.
COPYRIGHT VIOLATION WARNING: “Rhythm Pharmaceuticals (RYTM) Earns News Sentiment Rating of 0.08” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/10/30/rhythm-pharmaceuticals-rytm-earns-news-sentiment-rating-of-0-08.html.
In related news, Director David P. Meeker acquired 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $425,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder S.A. Ipsen acquired 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The shares were bought at an average price of $17.00 per share, with a total value of $340,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 1,285,000 shares of company stock valued at $21,845,000.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
What are top analysts saying about Rhythm Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Rhythm Pharmaceuticals Inc. and related companies.